• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

    6/20/25 7:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.
    • Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.

    CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes to eat better and feel healthier, with participants reporting improved diet quality and health status.

    This study is one of the few randomized controlled clinical trials examining the impact of food is medicine programs. Conducted by the Public Health Institute Center for Wellness and Nutrition (PHI CWN), this clinical trial assessed the impact of Abbott's Healthy Food Rx in a highly food insecure, low-income, community-based setting of 364 people living with diabetes over a six-month period. The Healthy Food Rx program provides home-delivered, meal-based healthy food boxes accompanied by nutrition education to help address diabetes.

    Key study results include:

    • Improved diet quality: Healthy Food Rx participants reported significantly increased vegetable consumption compared to the control group (0.37 vs. 0.03 increased servings per day; p = 0.007), and increased fruit consumption compared to control group (0.3 vs. 0.2 increased servings per day, p = 0.232).
    • Improved health status: Healthy Food Rx participants reported significantly greater improvements in self-reported physical health status over six months (from 38% to 63%, p < 0.001), compared to the control group (from 47% to 50%, p=0.453; between group p<0.001).
    • Lowered A1C levels in both groups: A1C levels significantly improved for both Healthy Food Rx participants and the control group. A1C is a test that reflects average glucose levels for the past three months; levels decreased by 0.7% and 1.2%, in the intervention group and control group, respectively. Both values exceeded the widely accepted 0.5% benchmark that is considered a clinically significant change and is associated with improved health outcomes in people with diabetes.
    • Participants were strongly satisfied with Healthy Food Rx, and shared with family and friends. Participants in Abbott's Healthy Food Rx reported strong satisfaction – 98% were satisfied with the program and 97% used all or most of the food. Two-thirds of participants (67%) shared the food with two or more people, and 99% were likely to recommend the program to others.

    "Living with diabetes in an economically underserved community can present numerous challenges, from limited access to affordable, healthy foods to a lack of appropriate health services," said Erika Takada, Executive Director, Public Health Institute Center for Wellness and Nutrition. "Even with a program that reaches participants just twice a month, we are seeing benefits in people with diabetes eating better foods and feeling healthier. This underscores the foundational role that good nutrition can play in helping to address the impact of diabetes and other chronic diseases on our families and communities."

    Launched in 2021, Abbott's Healthy Food Rx is one of the largest community-focused food is medicine programs in the country, reaching more than 1,700 participants to date. These clinical trial findings build on results of an earlier 12-month study that showed clinically important benefits among Healthy Food Rx participants living with diabetes.

    "Programs like Abbott's Healthy Food Rx are critically important in communities like Stockton where diabetes incidence and risk are significantly higher," said Kwabena O. Adubofour, MD, FACP, Internal Medicine Specialist and a Board Certified Diabetologist at Community Medical Centers (CMC) in Stockton. "From results like A1C reduction to even personal well-being, participants from the CMC clinic benefited greatly from access to healthy foods and nutrition resources. It will be important to see how these benefits translate into long-term improvements in diabetes outcomes so people can lead healthier, fuller lives."

    "We're pleased that results from Abbott's Healthy Food Rx can contribute to a better understanding of the impacts that programs like this can have for people living with diabetes," said Melissa Brotz, president of Abbott Fund and senior vice president of Global Marketing and External Affairs at Abbott. "By integrating healthy food and nutrition education as part of a broader effort to remove barriers to care, we're helping people to feel more in control and take an active role in managing their health."

    About the Clinical Trial

    A delayed intervention randomized clinical trial design was used. Participants were recruited by health educators and randomized into two groups: the intervention group received home-delivered, meal-based food boxes once every other week for six months with nutrition education in the form of recipes, cooking videos and text messages; the control group received the intervention after the six-month study period. All participants received usual care, including potential medication prescriptions and optional diabetes education and social needs referrals.

    Participants were administered surveys at enrollment and after six months, with hemoglobin A1C assessed as the primary outcome, and secondary outcomes including fruit and vegetable intake, food security and health status. Study results can be found here.

    About Abbott's Healthy Food Rx

    Abbott's Healthy Food Rx program is part of the company's Future Well™ Communities initiative, a multi-year effort to advance health access by removing the barriers that prevent people with diabetes from living healthy lives.

    Abbott partnered with PHI CWN to design and implement Healthy Food Rx with Stockton-based organizations, with funding support from Abbott's foundation, Abbott Fund. CMC, a local federally qualified health center in Stockton, identified potential Healthy Food Rx participants. Program participants received food boxes from the Emergency Food Bank Stockton/San Joaquin (EFB), delivered directly to their home every other week for six months. The boxes included ingredients for a family-sized healthy meal with lean protein, vegetables and fruits, as well as pantry staples such as beans, rice and nuts. The box also contained a recipe card and link to an optional online cooking class with EFB, which provided additional guidance and diabetes education.

    About the Public Health Institute and the Center for Wellness and Nutrition

    The Public Health Institute, an independent nonprofit organization, advances wellbeing and health equity with communities around the world. PHI develops research, leadership and partnerships to build strong public health policy, programs, systems and practices. For more information, visit phi.org. The Center for Wellness and Nutrition (CWN, centerforwellnessandnutrition.org), a program of the Public Health Institute, is a national leader in developing campaigns, programs and partnerships to promote wellness and equitable practices in the most vulnerable communities in California and across the country.

    About Abbott and Abbott Fund

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    Abbott Fund is a philanthropic foundation established by Abbott in 1951. Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide. For more information on Abbott Fund, visit www.abbottfund.org.

    Cision View original content:https://www.prnewswire.com/news-releases/new-research-on-abbotts-healthy-food-rx-program-shows-food-is-medicine-approach-helps-people-living-with-diabetes-eat-better-and-feel-healthier-302487489.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ABT
    SEC Filings

    View All

    SEC Form 10-Q filed by Abbott Laboratories

    10-Q - ABBOTT LABORATORIES (0000001800) (Filer)

    7/30/25 4:14:29 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    7/17/25 7:34:53 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Abbott Laboratories

    11-K - ABBOTT LABORATORIES (0000001800) (Filer)

    6/20/25 4:05:52 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Big Ten Conference Rally Students, Alumni, and Fans to Save Lives and Win $1 Million for Their School by Donating Blood This College Football Season

    All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood donations from students, alumni, and fans with the winning school earning $1 million from Abbott for student or community healthAbbott is releasing exclusive, limited-edition Homefield designed T-shirts for each Big Ten school. Be among the first to receive one by showing up to donate on 'We Give Blood Day' on Aug. 27Abbott launched the 'We Give Blood' drive in response to the worst U.S. blood shortages in decades, aiming to inspire the next generation of donorsThe 2025 winner will be announced at the 2025 Discover Big Ten Football Championship Game on

    8/18/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Reports Second-Quarter 2025 Results

    Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increaseReported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percen

    7/17/25 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

    MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies.  AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often devel

    7/15/25 8:45:00 AM ET
    $ABT
    $DXCM
    $IRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    EVP AND CFO Boudreau Philip P sold $746,758 worth of Common shares without par value (5,550 units at $134.55), decreasing direct ownership by 10% to 51,003 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    8/11/25 5:53:04 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Stratton John G

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    7/1/25 5:32:18 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Roman Michael F

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    7/1/25 5:24:18 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Abbott Labs with a new price target

    Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

    10/8/24 7:11:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott Reports Second-Quarter 2025 Results

    Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increaseReported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percen

    7/17/25 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Hosts Conference Call for Second-Quarter Earnings

    ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

    6/26/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Declares 406th Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 406th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio

    6/13/25 11:34:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

    1/6/25 9:00:00 AM ET
    $ABT
    $BMY
    $IRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate